中共党员陈薇是中国人民解放军少将，军事医学科学院生物工程研究所所长、研究员，2001年“9·11事件”后不久作为中国人民解放军重大专项的首席科学家，获得500多万元的资助，2006年凭借一项所谓反恐生化研究以第一完成人身份获得中国人民解放军军队科学技术进步奖一等奖。
#Democracy #Christ #Peace #Freedom #Liberty #Humanrights #人权 #法治 #宪政 #独立审计 #司法独立 #联邦制 #独立自治
Civil–Military Biomedical Integration: Zhejiang University, Overseas Medical Networks, and the Academy of Military Sciences
Feng Jianwei, Permanent Honorary President of the Shandong Fellowship Association of Southern U.S.A., has played a role in organizing transnational medical initiatives linking U.S.-based physicians with institutions in the People’s Republic of China.
In 2005, he participated in founding the American Houpu Biomedical Education and Development System, which reportedly facilitated recruitment into state-sponsored talent initiatives, including the “Thousand Talents Plan” and “Changjiang Scholars Program.”
In 2015, Feng and other U.S.-based Chinese medical professionals launched the American Chinese Physicians Network Hospital.
That same year and following years, Feng received high-level political visibility within the CCP system, including meetings with senior national leadership and participation in the Chinese People’s Political Consultative Conference (CPPCC). Such recognition reflects incorporation into formal united front and overseas professional engagement channels.
On December 26, 2015, Zhejiang University School of Medicine’s Second Affiliated Hospital (ZJU-2 Hospital) and the American Chinese Physicians Network Hospital jointly established the “China Southern Center.”
On May 20, 2021, Zhejiang University School of Medicine issued a public announcement regarding its joint doctoral training program with the Academy of Military Sciences (AMS).
The notice confirms:
Formal joint recruitment procedures
Shared evaluation by ZJU and AMS faculty teams
In-person written exams and interviews at ZJU’s Hangzhou campus
Alignment with ZJU’s official doctoral admissions framework
Two AMS-affiliated “innovation teams” were explicitly named:
Zhang Xue-Min Innovation Team
Chen Wei Innovation Team
Amway China R&D Center’s Jun Guo: On Stage with PLA-Affiliated Researchers
Jun Guo Product Safety Manager at Amway (China) R&D Center once worked at PLA Academy of Military Medical Sciences(AMMS) prior to joining Amway (China), but in a session she directly shared the stage with PLA AMMS and PLA CDC researchers, in a session they chaired and moderated, and at a conference led by a senior PLA scientist.
In Shanghai, April 14–17, 2019, the 2019 Workshop on Cosmetic Risk Assessment and Regulatory Application of Non-Animal Testing Technology brought together Chinese and international toxicology experts, corporate R&D representatives, and animal welfare organizations. The event was hosted by the Society of Toxicological Alternatives & Translational Toxicology (CSOT) and the Society of Toxicity Testing and Alternative Methods (CEMS), with sponsorship from Humane Society International, L’Oréal R&I China, Mary Kay (China) Co., Ltd., and Shanghai Medicilon Inc..
The organizing committee included: Conference Chair Peng Shuangqing, Secretaries Xiaoting Qu and Yi Shuai, and members such as Jiabin Guo (co-author on PLA-affiliated research), Kate Willett, and multiple other academics and industry representatives. The workshop program featured plenary lectures and focused sessions led by international and Chinese experts:
Gerald Renner (Cosmetic Europe) on EU regulatory implementation;
Kate Willett (Humane Society International) on non-animal safety assessment and OECD Adverse Outcome Pathway programs;
Vera Rogiers (Vrije Universiteit Brussel / EU SCCS) on in vitro toxicology and cosmetic risk assessment;
James Wakefield (Delphic HSE) on regional toxicological safety and compliance in APAC;
Lit-Hsin Loo (A*STAR, Singapore) on toxicity mode-of-action profiling;
Yuan Gao (P&G) and Jin Li (Unilever, UK) on non-animal testing integration and pathway-based risk assessment;
Taoran Xing (L’Oréal APAC) and Liping Hu (Johnson & Johnson, China) on regulatory product safety evaluation in the Asia-Pacific region.
Other key speakers at the 2019 Workshop on Cosmetic Risk Assessment and Regulatory Application of Non-Animal Testing Technology included internationally recognized experts in alternative testing and toxicology. Donna Macmillan, Principal Scientist at Lhasa Limited, leads the skin sensitization research team and promotes collaborative data-sharing to improve predictive toxicity models. Hajime Kojima, Secretary General of the Japanese Center for the Validation of Alternative Methods (JaCVAM) and Section Chief of the Division of Risk Assessment at Japan’s Biological Safety Research Center, also serves as a councilor for multiple Japanese toxicology and alternative methods societies and is an OECD expert on skin and eye irritation, sensitization, and endocrine disruptor testing. Carl Westmoreland, Director of Science & Technology at Unilever’s Safety and Environmental Assurance Centre (SEAC), focuses on delivering consumer safety without animal testing and is a member of the European Scientific Advisory Committee for ECVAM. Nathalie Alépée of L’Oréal R&I France has over twenty years of leadership in investigative toxicology, contributing to EU alternative testing projects, ESAC, and OECD regulatory guidance.
China Mergers & Acquisitions Association Is Not a Trade Group — It’s a CCP United Front Instrument
Based on its own charter, leadership endorsements, and political positioning, CMAA (全联并购公会) is not an independent market institution. It is a Chinese Communist Party (CCP)–embedded united front organization, operating under the direct leadership of the CCP’s political, ideological, and organizational apparatus.
Official Identity: A CCP-Supervised Organization
CMAA’s full English name is China Mergers & Acquisitions Association, abbreviated CMAA. It is registered in Beijing and operates under:
Business supervision: All-China Federation of Industry and Commerce (ACFIC)
Registration authority: Ministry of Civil Affairs of the People’s Republic of China
Political leadership: Chinese Communist Party
Its charter openly states that the organization:
Upholds Socialism with Chinese Characteristics
Takes Marxism–Leninism, Mao Zedong Thought, Deng Xiaoping Theory, the “Three Represents,” the Scientific Outlook on Development, and Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era as its guiding ideology
Fully implements the CCP’s line, principles, and policies
Adheres to the principle of the CCP’s comprehensive leadership
Shen Ying, Deputy Head of the CCP Central Committee’s United Front Work Department. She explicitly instructed CMAA to:
Treat implementation of CCP plenary decisions as a “major political task”
Raise “political standing” and “political direction”
Translate CCP Central Committee decisions directly into association action
Align its work with Central Economic Work Conference priorities
This is not advisory language. It is command language.
Subscribe to:
Comments (Atom)
